Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 277-283

  Wang, Zhen ji ^a   Liu, Quan ^a   Li, Ping ping ^a   Zou, Chen hui ^a   Shen, Zhu fang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

GCP 02; Insulin resistance; PPARalpha gamma dual activator; Rosiglitazone

Indexed keywords

2 ETHOXY 3 [4 [2 (4 TRIFLUOROMETHANESULFONYLOXYPHENYL)ETHOXY]PHENYL]PROPIONIC ACID; ALANINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; GCP 02; GLUTAMATE SODIUM; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MALONALDEHYDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCOGEN ANALYSIS; HEART MUSCLE; HEART WEIGHT; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID METABOLISM; LIVER; LIVER WEIGHT; LOW DRUG DOSE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLEUS MUSCLE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADMINISTRATION, ORAL; ANIMALS; ARYLSULFONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; MICE; MICE, INBRED ICR; PHENYLPROPIONATES; PHOSPHOPROTEINS; PPAR ALPHA; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 37649006829     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.042     Document Type: Article

References (22)

1. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23 (2000) 1605-1611
2. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., and Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 716-726
3. Brand C.L., Sturis J., Gotfredsen C.F., Fleckner J., Fledelius C., Hansen B.F., Andersen B., Ye J.M., Sauerberg P., and Wassermann K. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E841-E854
4. Buse J.B., Rubin C.J., Frederich R., Viraswami-Appanna K., Lin K.C., Montoro R., Shockey G., and Davidson J.A. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27 (2005) 1181-1195
5. Cai Z., Liu Q., Li P., Guo Z., and Shen Z. Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid. Acta Pharmacologica Sinica 27 (2006) 597-602
6. Chakrabarti R., Misra P., Vikramadithyan R.K., Premkumar M., Hiriyan J., Datla S.R., Damarla R.K., Suresh J., and Rajagopalan R. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-alpha and PPAR-gamma. Eur. J. Pharmacol. 491 (2004) 195-206
7. Cheung C., Akiyama T.E., Ward J.M., Nicol C.J., Feigenbaum L., Vinson C., and Gonzalez F.J. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 64 (2004) 3849-3854
8. Florkowski C.M. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Am. J. Cardiovasc. Drugs 2 (2002) 15-21
9. Ginsberg H.N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106 (2000) 453-458
10. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am. J. Cardiol. 90 (2002) 3G-10G
11. Kraegen E.W., Cooney G.J., Ye J., and Thompson A.L. Triglyceride, fatty acids and insulin resistance-hyperinsulinemia. Exp. Clin. Endocrinol. Diabetes 109 (2001) S516-S526
12. Kramer D., Shapiro R., Adler A., Bush E., and Rondinone C.M. Insulin-sensitizing effect of rosiglitazone(BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 50 (2001) 1294-1300
13. Liu K., Xu L., Berger J.P., Macnaul K.L., Zhou G., Doebber T.W., Forrest M.J., Moller D.E., and Jones A.B. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia. J. Med. Chem. 48 (2005) 2262-2265
14. Macho L., Fickova M., Jezova D., and Zorad S. Late effects of postnatal administration of monosodium glutamate on insulin action in adult rats. Physiol. Res. 49 (2000) S9-S85
15. Martens F.M., Visseren F.L., Lemay J., de Koning E.J., and Rabelink T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2 (2002) 1463-1480
16. Masoudi F.A., Wang Y., Inzucchi S.E., Setaro J.F., Havranek E.P., Foody J.M., and Krumholz H.M. Metformin and thiazolidinedione use in medicare patients with heart failure. JAMA 290 (2003) 81-85
17. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., and Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941-2948
18. Petit D., Bonnefis M.T., Rey C., and Infante R. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis 74 (1988) 215-225
19. Scheen A.J. Thiazolidinediones and liver toxicity. Diabetes Metab. 27 (2001) 305-313
20. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
21. Tenenbaum A., Motro M., and Fisman E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. 4 (2005) 14-18
22. Ye J.M., Dzamko N., Cleasby M.E., Hegarty B.D., Furler S.M., Cooney G.J., and Kraegen E.W. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47 (2004) 1306-1313